A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Ono Sues AstraZeneca over PD-L1 Patent, Seeks 32 Billion Yen in Damage
March 1, 2022
-
REGULATORY MHLW Approves Label Expansions for Retevmo, Keytruda, Lenvima and More
February 28, 2022
-
ORGANIZATION Impact of Ukraine Invasion Limited in Japan? Trader Group Says Epirubicin Is Only API Possibly Affected
February 25, 2022
-
BUSINESS Tokyo Court Rejects Chugai’s Claim over Edirol Substance Patent
February 25, 2022
-
BUSINESS Medicago’s COVID-19 Vaccine Approved in Canada
February 25, 2022
-
ORGANIZATION Chuikyo Payer Rep Wants Category-Based Debate on Adjustment Rate, Prods PMP Cuts in Next Off-Year Revision
February 24, 2022
-
BUSINESS Bayer Gets Eylea Biosame Approval in Japan as It Braces for Biosimilar Debuts
February 22, 2022
-
BUSINESS Sleep Inducer Recalls by Fuji Yakuhin, Tatsumi Kagaku Tied to Tokyo Wholesaler’s Fake API Case
February 21, 2022
-
REGULATORY Japan Weighs Pre-Approval Purchase of Shionogi’s COVID-19 Pill
February 21, 2022
-
BUSINESS Chugai Claims 1st-Ever Title in Japan Pharma Market in 2021 on Brisk Oncologic Performance: IQVIA
February 18, 2022
-
BUSINESS Sawai to Launch Teribone Generic as Court Invalidates Patents; Asahi Kasei to Challenge Ruling
February 17, 2022
-
REGULATORY Japan Approves Slew of Generics towards June Listing; Samsca, Xarelto AGs Too
February 16, 2022
-
BUSINESS Pharma Officials Air Hopes and Concerns as Japan Moves to Enhance Supply Chain for Economic Security
February 15, 2022
-
REGULATORY Japan Snags 10 Million Extra Doses of Pfizer Vaccine
February 15, 2022
-
BUSINESS Chugai Joins Top Ranks in Japan Sales on Ronapreve Boon, Roche Collaboration
February 14, 2022
-
REGULATORY Pfizer’s Paxlovid Contraindicated with Many Medicines, Requires Careful Use
February 14, 2022
-
REGULATORY Japan Approves Pfizer’s Paxlovid, Second Oral COVID-19 Pill
February 10, 2022
-
ORGANIZATION Govt-Industry Arrangement for Drug Supply Survey Hits Rough Waters; FPMAJ Stands Pat on Continued Dialogue
February 10, 2022
-
REGULATORY Chuikyo Issues 2022 Reform Recommendation; Patch Prescription Limit Lowered to 63 Sheets
February 10, 2022
-
BUSINESS Chugai Sees Huge Potential in Its RAS Inhibitor with 15% of All Cancers Targeted: Research Chief
February 9, 2022
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…